期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
New antigens involved in membranous nephropathy beyond phospholipase A2 receptor 被引量:2
1
作者 Maurizio Salvadori Aris Tsalouchos 《World Journal of Nephrology》 2022年第4期115-126,共12页
When the physiopathology of membranous nephropathy was first described,almost 30%of cases were recognized to be secondary to well-known diseases such as autoimmune diseases,tumors or infections.The remaining 70%cases ... When the physiopathology of membranous nephropathy was first described,almost 30%of cases were recognized to be secondary to well-known diseases such as autoimmune diseases,tumors or infections.The remaining 70%cases were called primary membranous nephropathy as the exact mechanism or pathogenic factor involved was unknown.The discovery of the M type phospholipase A2 receptor and thrombospondin type 1 domain containing 7A as causative antigens in these“so called”primary membranous nephropathies provided new insights into the effective causes of a large proportion of these cases.Novel techniques such as laser microdissection and tandem mass spectrometry as well as immunochemistry with antibodies directed against novel proteins allowed the confirmation of new involved antigens.Finally,using confocal microscopy to localize these new antigens and immunoglobulin G and Western blot analysis of serum samples,these new antigens were detected on the glomerular membrane,and the related antibodies were detected in serum samples.The same antigens have been recognized in some cases of secondary membranous disease due to autoimmune diseases,tumors and infections.This has allowed examination of the relationship between antigens in primary membranous nephropathy and their presence in some secondary nephropathies.The aim of this study is to describe the characteristics of the new antigens discovered and their association with other diseases. 展开更多
关键词 Membranous nephropathy Exostosin½ Neural cell adhesion molecule 1 Neural epidermal growth factor like-1 protein Protocadherin 7 Semaphorin 3b
下载PDF
肝细胞癌中Semaphorin3B蛋白的表达及其临床意义 被引量:1
2
作者 李广振 靳斌 +3 位作者 郑立杰 高延超 魏猛 张宗利 《中华肝胆外科杂志》 CAS CSCD 北大核心 2013年第2期147-150,共4页
目的研究肝细胞癌(hepatocellular carcinoma,HCC)中Semaphorin3B(SEMA3B)蛋白的表达及其临床意义。方法运用Western blotting及免疫组化检测56例肝细胞癌患者肝癌组织、相应癌旁组织以及14例正常肝组织中SEMA3B蛋白的表达情况。... 目的研究肝细胞癌(hepatocellular carcinoma,HCC)中Semaphorin3B(SEMA3B)蛋白的表达及其临床意义。方法运用Western blotting及免疫组化检测56例肝细胞癌患者肝癌组织、相应癌旁组织以及14例正常肝组织中SEMA3B蛋白的表达情况。用血管内皮CD34(4-)计数确定微血管密度(MVD)。分析SEMA3B表达与临床病理指标之间的关系。结果肝细胞癌组织SEMA3B的阳性率为42.9%,低于正常肝组织及癌旁组织(阳性率分别为78.6%、85.7%,P〈0.05)。肝细胞癌组织SEMA3B阳性组的MVD值明显低于SEMA3B阴性组(P〈0.05)。SEMA3B的表达与肿瘤结节数、大小、有无完整包膜及CLIP评分密切相关(P均〈0.05)。SEMA3B阳性组的复发转移率明显低于阴性组(P〈0.05),阳性组的生存率显著高于阴性组(P〈0.05)。结论SEMA3B蛋白在肝细胞癌癌组织表达水平降低,与肿瘤发展、血管形成及预后密切相关,提示SEMA3B可作为评价预后的指标,可能为肝细胞癌患者新的抗血管治疗靶点。 展开更多
关键词 肝细胞癌 Semaphorin3b 微血管密度 复发 预后
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部